Galectin Therapeutics Inc. has provided an update on its focused pipeline of galectin-based therapeutics targeting chronic liver diseases and cancer. The company's lead compound, belapectin, is a galectin-3 inhibitor with Fast Track Designation and patent protection through 2032. Belapectin is being investigated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension, with clinical data showing a significant reduction in the incidence of new varices in patients compared to placebo. Additionally, combination studies with belapectin and Keytruda are underway for melanoma and head and neck cancers, following FDA approval to proceed. Preclinical data indicate belapectin is well-tolerated in animal models and reduces markers of fibrosis and portal pressure. The company is also advancing a discovery program for oral galectin-3 inhibitors. You can access the full presentation through the link below.